top of page

After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work

  • Writer: agbiopro
    agbiopro
  • Mar 15, 2020
  • 1 min read

Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work.


 
 
 

Comments


bottom of page